A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy-Reference-Cited by-同舟云学术

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Published:2020-10 Issue:10 Volume:31 Page:1397-1404
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Park S.,Lee M.-H.,Seong M.,Kim S.T.,Kang J.-H.,Cho B.C.,Lee K.H.,Cho E.K.,Sun J.-M.,Lee S.-H.,Ahn J.S.,Park K.,Ahn M.-J.

Funder

Astra Zeneca

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference25 articles.

1. LBA5_PR osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis;Ramalingam;Ann Oncol,2019

2. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer;Soria;N Engl J Med,2017

3. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC 2019;Ramalingam;N Engl J Med,2020

4. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer;Wu;Lung Cancer,2019

5. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers;Rangachari;Lung Cancer,2015

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape;Cancer Treatment Reviews;2024-11

2. Comparison of intracerebrospinal fluid methotrexate by Ommaya reservoir versus lumbar puncture in leptomeningeal carcinomatosis with hydrocephalus: a retrospective cohort study;2024-09-08

3. Treatment Advances in Lung Cancer with Leptomeningeal Metastasis;Current Cancer Drug Targets;2024-09

4. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM);Journal of Clinical Oncology;2024-08-10

5. Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitor Therapy;Journal of Clinical Oncology;2024-08-10